Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00985647

Pharmacokinetics of Lamivudine at Two Different Doses (ENCORE2)

Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC-Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV-Negative Healthy Volunteers

Sponsor: Kirby Institute

Conditions HIV Infections

Interventions Lamivudine (3TC)

Updated 6 times since 2017 Last updated: Feb 9, 2011 Started: Dec 31, 2009 Primary completion: Feb 28, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates HIV Infections and is currently completed. Kirby Institute leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kirby Institute

Data source: Kirby Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom